ArticleMolecular medicine reports2026
LINC01117 promotes the malignant proliferation of lung adenocarcinoma by increasing HOXD8 mRNA stability.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the functional role and molecular mechanisms of long intergenic non‑protein coding RNA 1117 (LINC01117) in lung adenocarcinoma (LUAD). Bioinformatics analysis was performed to assess the expression level and prognostic value of LINC01117. Gene expression in LUAD and lung squamous cell carcinoma tissues was determined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), and gene and protein expression levels in LUAD cells were detected using RT‑qPCR and western blotting, respectively. Cell Counting Kit‑8, 5‑ethynyl‑2'‑deoxyuridine, live cell imaging and colony formation assays were used to evaluate the proliferation of LUAD cells. Actinomycin D was used to inhibit RNA transcription. The results indicated that LINC01117 was significantly upregulated in both LUAD and lung squamous cell carcinoma, and its elevated expression was positively associated with poor prognosis in LUAD. Knockdown of LINC01117 inhibited cell proliferation, whereas its overexpression promoted proliferation. Furthermore, LINC01117 exhibited positive co‑expression with the transcription factor homeobox D8 (HOXD8); knockdown or overexpression of LINC01117 reduced or increased HOXD8 expression at both the RNA and protein levels, respectively. Conversely, HOXD8 knockdown did not significantly alter LINC01117 expression; however, HOXD8 knockdown inhibited cell proliferation and reversed the pro‑proliferative effects induced by LINC01117 overexpression. Mechanistically, LINC01117 was associated with increased HOXD8 mRNA stability. In conclusion, LINC01117 may serve as a notable prognostic biomarker that promotes cell proliferation in LUAD. HOXD8 may function as a downstream target of LINC01117, with LINC01117 exerting its pro‑proliferative effects by increasing HOXD8 mRNA stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.